Plandaí Biotechnology (PLPL) 10-Q 17 Aug 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2016	Aug. 15, 2016
Document And Entity Information
Entity Registrant Name	Plandai Biotechnology, Inc.
Entity Central Index Key	1,317,880
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		186,531,236
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,016

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Current Assets:
Cash	$ 7,962	$ 33,619
Inventory	54,004	2,286
Accounts Receivable	47,997	17,122
Other Current Assets	66,387	365,132
Total Current Assets	176,350	418,159
Deposits	64,678	75,246
Other Assets	108,468	1,220
Fixed Assets - Net	6,276,292	8,009,956
Total Assets	6,625,788	8,504,581
Current Liabilities:
Accounts Payable and Accrued Expenses	476,349	316,345
Accrued Interest	598,410	288,612
Convertible Notes Payable, net of discount	8,331
Derivative Liability	347,917
Current Portion of Long Term Debt	13,942,020	14,526,213
Note Payable to Related Party	50,526
Related Party Payables	14,890	16,177
Total Current Liabilities	15,438,443	15,147,347
Other Liabilities	133,086	159,994
Deferred Lease Obligation	1,501,182	1,513,976
TOTAL LIABILITIES	17,072,711	16,821,317
STOCKHOLDERS' DEFICIT
Common Stock, authorized 500,000,000 shares, $0.0001 par value, 180,406,236 and 164,419,936 shares issued and outstanding as of March 31, 2016 and June 30, 2015	18,041	16,442
Additional Paid-In Capital	30,685,041	30,124,629
Common Stock Issuable	50,000	45,000
Accumulated Deficit	(39,324,396)	(36,309,281)
Cumulative Foreign Currency Translation Adjustment	199,280	(375,880)
Total Stockholders' Deficit	(8,372,034)	(6,499,090)
Non-controlling Interest	(2,074,889)	(1,817,646)
Equity Allocated to Plandai Biotechnology	(10,446,923)	(8,316,736)
Total Liabilities and Stockholders' Deficit	$ 6,625,788	$ 8,504,581

Consolidated Balance Sheets (U3

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2016	Jun. 30, 2015
Statement of Financial Position [Abstract]
Common stock, par value per share	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	180,406,236	164,419,936
Common stock, shares outstanding	180,406,236	164,419,936

Consolidated Statements Of Oper

Consolidated Statements Of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenues	$ 100,295	$ 21,744	$ 197,798	$ 64,024
Expenses:
Production Costs	194,396	181,214	627,506	583,506
Payroll	225,478	5,079,803	623,318	6,128,980
Rent	75,978	107,859	250,507	325,121
Professional Services	17,334	80,597	182,714	455,161
Depreciation	118,609	46,695	393,678	139,517
General and Administrative	193,399	514,834	411,194	802,147
Total Expenses	825,194	6,011,002	2,488,917	8,434,432
Operating Loss	(724,899)	(5,989,258)	(2,291,119)	(8,370,408)
Other Income (Expense)
Other Income		12,765	273,922	777,724
Change in Derivative Liability	5,330		9,077
Interest Expense	375,242	296,292	1,006,996	552,344
Net Loss	(1,094,811)	(6,272,785)	(3,015,116)	(8,145,028)
Allocation to Non-Controlling Interests	(82,585)	(120,962)	(257,243)	(192,867)
Net Loss, Adjusted	(1,012,226)	(6,151,823)	(2,757,873)	(7,952,161)
Other Comprehensive Income (loss):
Foreign Currency Translation Adjustment	(74,907)	145,449	575,160	(432,361)
Comprehensive Income (Loss)	$ (1,087,133)	$ (6,006,374)	$ (2,182,713)	$ (8,384,522)
Basic & diluted loss per share	$ (0.01)	$ (0.04)	$ (0.02)	$ (0.06)
Weighted Avg. Shares Outstanding	175,663,325	140,845,731	169,034,016	135,224,529

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (3,015,116)	$ (8,145,028)
Adjustments to reconcile net loss to net cash (used in) operating activities:
Depreciation	393,678	139,517
Amortization of Debt Discount	52,691
Stock Issued or Payable for Services	273,350	5,971,536
Derivative Interest	85,936
Change in value of Derivative Liability	9,077
Addition to Notes Payable from Interest Added to Principal	559,529
Changes in Assets and Liabilities:
(Increase) Decrease in Accounts Receivable	34,665	(1,092)
Decrease (Increase) in Prepaid Expenses and Other Current Assets	(257,668)	134,920
Decrease in Related Party Receivable		(426,444)
(Increase) Decrease in Deposits	(2,277)	8,125
Increase in Inventory	53,467	985
(Increase) Decrease in Other Assets	111,300	(71,330)
Increase in Accounts Payable and Accrued Expenses	212,124	73,865
Increase in Deferred Lease Obligation	250,853	139,517
Increase (Decrease) in Related Party Payables	1,462	(2,949)
Increase in Other Liabilities		178,363
Increase in Accrued Interest	309,798	158,253
Net Cash Used in Operating Activities	(828,813)	(1,115,840)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of Fixed Assets	11,379	752,083
Net Cash Used in Investing Activities	(11,379)	(752,083)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Issuing Long Term Debt, Net of Discount	400,000	1,988,396
Proceeds from Issuing Convertible Debt	275,000
Proceeds from Issuing Notes to Related Party	50,526
Principal Payments on Long Term Debt	154,009
Proceeds from the Sale of Common Stock	293,660	286,700
Net Cash Provided by Financing Activities	865,177	2,275,096
Effect of Exchange Rates on Cash Flows	(50,642)	(435,757)
Net Increase (Decrease) in Cash and Cash Equivalents	(25,657)	(28,584)
Cash and Cash Equivalents at Beginning of Period	33,619	156,570
Cash and Cash Equivalents at End of Period	7,962	127,986
NON-CASH INVESTING AND FINANCING ACTIVITIES
Shares issued to retire debt		24,674
Interest expense added to loan principal	559,529
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid during the year for: Interest		220,643
Cash paid during the year for: Taxes

Nature Of Operations And Going

Nature Of Operations And Going Concern	9 Months Ended
	Mar. 31, 2016
Nature Of Operations And Going Concern
Nature of Operations and Going Concern	NOTE 1 – NATURE OF OPERATIONS AND GOING CONCERN Plandaí Biotechnology, Inc.’s (the “Company” or “Plandaí”) consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustment relating to recoverability and classification of recorded amounts of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. The Company's continued existence is dependent upon its ability to continue to execute its operating plan and to obtain additional debt or equity financing. There can be no assurance the necessary debt or equity financing will be available, or will be available on terms acceptable to the Company. Plandaí and its subsidiaries focus on the development and production of proprietary botanical extracts for the nutraceutical and pharmaceutical industries. The Company grows much of the live plant material used in its products on a 3,237 hectare (approx. 8,000 acre) estate it operates under a 49-year notarial lease in the Mpumalanga region of South Africa. Plandaí uses a proprietary extraction process that is designed to yield highly bioavailable products of pharmaceutical-grade purity. The first product brought to market was Phytofare™ Catechin Complex, a green-tea derived extract that has multiple potential wellness applications. Additional extracts utilizing citrus, artemisia, and cannabis are in various stages of development and testing. The Company’s principle holdings consist of land, farms and infrastructure in South Africa. The Company is actively pursuing additional financing and has had discussions with various third parties, although no firm commitments have been obtained. Management believes these efforts will generate sufficient cash flows from future operations to pay the Company's obligations and realize positive cash flow. There is no assurance any of these transactions will occur.

Summary Of Accounting Policies

Summary Of Accounting Policies	9 Months Ended
	Mar. 31, 2016
Summary Of Accounting Policies
Summary of Accounting Policies	NOTE 2 – SUMMARY OF ACCOUNTING POLICIES Basis of Presentation The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The accompanying financial statements represent the results of operations for the three and nine months ended March 31, 2016 and March 31, 2015. The Company has adopted the US dollar as the reporting currency for accounting and reporting purposes. This summary of accounting policies for Plandaí Biotechnology, Inc. and its wholly-owned subsidiaries, is presented to assist in understanding the Company's financial statements. The accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the financial statements. Interim Financial Statements The accompanying financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to form 10Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion the financial statements include all adjustments (consisting of normal recurring accruals) necessary in order to make the financial statements not misleading. Operating results for the three and nine months ended March 31, 2016 are not necessarily indicative of the final results that may be expected for the year ended June 30, 2016. For more complete financial information, these unaudited financial statements should be read in conjunction with the audited financial statements for the year ended June 30, 2015 filed with the SEC. Use of Estimates The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America. In preparing the financial statements, management is required to make estimates and assumptions that effect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the balance sheet and statement of operations for the year then ended. Actual results may differ from these estimates. Estimates are used when accounting for allowance for bad debts, collect ability of accounts receivable, amounts due to service providers, depreciation and litigation contingencies, among others. Business Combinations and Acquisitions The disclosure requirements for business combination and acquisitions are intended to enable users of financial statements to evaluate the nature and financial effects of: • A business combination that occurs either during the current reporting period or after the reporting period, but before the financial statements are issued • Adjustments recognized in the current reporting period that relate to business combinations that occurred in current and previous reporting periods • The nature of the relationship between the parent and a subsidiary or investee when the parent does not have 100 percent ownership or control The Company discloses each material business combination in the period in which the business combination occurs. The Company also discloses information about acquisitions made after the balance sheet date, but before the financial statements are issued. Gains or losses arising from the deconsolidation of a business when the company loses control of that business are also disclosed. Acquisition costs incurred such as legal, advisory and consulting fees are expensed as incurred. In accordance with ASC 805-10-25-1, ASC 805-10-05-4 and IFRS 3.4, 5, the Company employs the Acquisition Method of accounting for routine acquisitions and combinations. Net Loss Per Common Share The Company adopted FASB ASC Topic 260, Earnings Per Share In January 2014, the Company issued warrants to purchase 5,000,000 shares of the Company’s common stock which have a strike price of $0.01/share; however, since the Company incurred a loss for all periods presented, the warrants are considered anti-dilutive. During the year ended June 30, 2015, a total of 1,666,666 warrants were exercised utilizing a “cashless” option resulting in the issuance of 1,629,212 shares of restricted common stock, leaving 3,333,334 outstanding exercisable warrants as of March 31, 2016. Reclassifications Prior year amounts have been reclassified to conform to the current year presentation. There was no net impact on total assets, net (loss), comprehensive (loss) or the statement of cash flows. Recent Accounting Pronouncements Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Fixed Assets

Fixed Assets	9 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Fixed Assets	NOTE 3 – FIXED ASSETS Fixed assets, stated at cost, less accumulated depreciation at March 31, 2016 and June 30, 2015 consisted of the following: March 31, June 30, Plant and Equipment $ 6,188,185 $ 7,487,506 Machinery and Equipment 172,172 211,283 Leasehold Improvements 666,320 752,530 Furniture and Fixtures 67,756 81,626 Automobiles 75,275 90,684 Computers and Equipment 19,263 23,206 Total Fixed Assets 7,188,971 8,646,835 Less: Accumulated Depreciation (912,679 ) (636,879 ) Fixed Assets, net $ 6,276,292 $ 8,009,956 The reduction in fixed assets results from a combination of depreciation expense and the fluctuation of the South African Rand against the U.S. Dollar, as all of the Company’s fixed assets are located in South Africa. Depreciation expense Depreciation expense for the three and nine months ended March 31, 2016 was $118,609 and $393,678 compared to $46,695 and $139,517 for the three and nine months ended March 31, 2015, respectively. The Company did not commence depreciating the leasehold improvements, plant and equipment, and other fixed assets associated with the factory until they were placed in service, January 1, 2015. The difference between accumulated depreciation and depreciation expense results from the application of the currency adjustment (see Note 8).

Segment Information

Segment Information	9 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Segment Information	NOTE 4 – SEGMENT INFORMATION Geographical Locations The following information summarizes the financial information regarding Plandaí Biotechnology Inc. and its operational South African subsidiaries for the periods presented: As of June 30, 2015: South Africa United States Total Assets $ 8,406,177 $ 98,404 $ 8,504,581 Liabilities $ 10,402,092 $ 6,419,225 $ 16,821,317 As of March 31, 2016 South Africa United States Total Assets $ 6,578,361 $ 47,427 $ 6,625,788 Liabilities $ 9,245,853 $ 7,826,858 $ 17,072,711 For the three-months ended March 31, 2016 South Africa United States Total Revenues from external customer $ 100,295 $ — $ 100,295 Expenses $ 468,508 $ 356,686 $ 825,194 Interest expense $ 179,031 $ 196,211 $ 375,242 Segment loss $ 547,244 $ 547,567 $ 1,094,811 For the nine-months ended March 31, 2016 South Africa United States Total Revenues from external customer $ 197,798 $ — $ 197,798 Expenses $ 1,545,972 $ 942,945 $ 2,488,917 Interest expense $ 556,070 $ 450,926 $ 1,006,996 Segment loss $ 1,630,322 $ 1,384,794 $ 3,015,116

Notes Payable

Notes Payable	9 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Notes Payable	NOTE 5 – NOTES PAYABLE As of the dates presented, the long-term loan balances were as follows: Interest Rate Due Date March 31, 2016 June 30, 2015 Loan Principle and Interest - Land Bank See below See below $ 7,369,404 $ 8,401,900 Notes Payable – other third party 6% July 1, 2016 6,900,000 6,500,000 Less: Discount (327,384 ) (375,687 ) 13,942,020 14,526,213 Less: Current Portion (13,942,020 ) (14,526,213 ) Long Term Debt, Net of Discount $ — $ — Notes Payable – other third party Between November 25, 2013 and June 4, 2015, the Company issued a total of $6,500,000 in notes payable to a third party, the proceeds from which were used for working capital purposes. In July 2015, the Company issued a note payable for $400,000 to the third party in exchange for cash of $384,170 and payment of expenses on behalf of the Company of $15,830. The note bears interest at 6% per annum and was originally due February 1, 2016. Collectively, these notes total $6,900,000 and $6,500,000 as of March 31 2016 and June 30, 2015, respectively, and were due and payable twelve months after issuance. The Company subsequently renegotiated the due date on each of these notes to July 1, 2016. The Company is not required to make monthly payments on any of these notes. As of March 31, 2016 and June 30, 2015, the Company recorded accrued interest pertaining to the outstanding notes payable in the amounts of $594,332and $288,612, respectively. Land and Agriculture Bank of South Africa In June 2012, the Company, through the majority-owned subsidiaries of Dunn Roman Holdings, Inc., executed final loan documents on a 100 million Rand (approx. $6.5 million USD at current rates) financing with the Land and Agriculture Bank of South Africa (“Land Bank”). The total loan is comprised of multiple agreements totaling, between Green Gold Biotechnologies (Pty) Ltd. and Breakwood Trading 22(Pty) Ltd., 100 million rand (approx. $6.5 million USD at current exchange rates). The loans all bear interest at the rate of prime plus 0.5% per annum and are all due in seven years. In addition, the loans have a 25-month “holiday” in which no payments or interest are due until 25 months after the first draw down of funds. The loans are collateralized by the assets and operations, including the Senteeko lease, agriculture production and receivables of Dunn Roman Holdings, which is the African operating arm of Plandaí. In addition, Dunn Roman Holdings was required to grant a 15% profit share agreement to the Land Bank which extends through the duration of the loan agreements (7 years unless pre-paid). The profit share agreement extends only to profits generated by Dunn Roman Holdings exclusive of operations of Plandaí and outside of South Africa. By way of loan covenants, the borrowing entities are required to maintain a debt to equity ratio of 1.5:1, interest coverage ratio of 1.5:1, and security coverage ratio of 1:1, none of which are currently in compliance. However, the Company consistently notified the Bank of this situation and has requested written documentation as to the Bank’s intention. The Bank has provided documentation extending the “holiday” at least through December 2016. As of and through the date of this report, the Land Bank has not provided any notice of default or requested compliance with the terms of the loans. During the year ended June 30, 2012, the Company issued 1,500,000 shares of restricted common stock to three Dunn Roman shareholders in exchange for their shares of Dunn Roman Holdings which had been previously issued. The acquired Dunn Roman shares were then provided to third parties in order to comply with the BEE provisions associated with the loan from the Land Bank of South Africa, which required that 15% of Dunn Roman be owned by non-white South Africans. The Company has therefore determined to treat the value of the shares issued to acquire the Dunn Roman stock ($585,000, based on the value of shares on the date of issuance) as a cost of securing the financing and recorded as a loan discount which is amortized over the life of the loan (7 years). During the three and nine months ended March 31, 2016 the Company amortized $16,101 and $48,303, respectively, leaving a debt discount balance of $327,384 at March 31, 2016. As of March 31, 2016, a total of $7,369,404, which includes capitalized accrued interest, was owed to the Land Bank. The proceeds were used to purchase fixed assets that are employed in South Africa to produce the Company’s botanical extracts, fund the rehabilitation of the Senteeko Tea Estate, including the repair of roads, bridges, and onsite management and farm worker housing, and the pruning, weeding and fertilizing of the plantation. As the 25-month holiday in which no payments or interest are due expired in July of 2014, the Company is required to make monthly payments of approximately 2,250,000 South African Rand (approximately $145,000 US Dollars). During the nine months ended March 31, 2016, the Company paid approximately $162,329 and accrued $559,088 in capitalized interest. Commencing August 2015, the Company ceased making payments to the Land Bank and has been in discussions to renegotiate the payment terms of the obligation. The Land Bank has been cooperative in this effort and has not expressed any intention to foreclose or accelerate the debt balances. Inasmuch as the Company is out of compliance with certain loan covenants including the non-payment of scheduled monthly amounts due under the various leases, the Company has elected to classify the entire balance owed to the Land Bank as “current” in the accompanying balance sheets as of March 31, 2016 and June 30, 2015. Future maturities of long-term debt are as follows: 2016 $ 8,640,000 2017 1,740,000 2018 1,740,000 2019 1,740,000 2020 82,020 $ 13,942,020

Notes Payable To Related Partie

Notes Payable To Related Parties	9 Months Ended
	Mar. 31, 2016
Notes Payable To Related Parties
Notes Payable to Related Parties	NOTE 6 – NOTES PAYABLE TO RELATED PARTIES On January 1, 2016, the Company borrowed £35,000 ($50,526 at March 31, 2016), from the son of Roger Baylis-Duffield, the Company’s Chief Executive Officer, the proceeds from which were used for general operating purposes. The note bears interest at the rate of 15% per annum, with interest due semi-annually, and the balance plus any accrued interest due and payable on December 31, 2016.

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Convertible Notes Payable	NOTE 7 – CONVERTIBLE NOTES PAYABLE Principal Balance Loan Discount Accrued interest Total June 30,2015 $ — $ — $ — $ — Issued in the period 292,500 (288,558 ) — 3,942 Converted into shares of common stock — — — — Payments of principal and interest — — — — Amortization of debt discount — 4,389 — 4,389 Interest accrued — — — — March 31, 2016 $ 292,500 $ (284,169 ) $ — $ 8,331 The Company evaluated the terms of the conversion features of its convertible debentures in accordance with ASC Topic No. 815 - 40, Derivatives and Hedging - Contracts in Entity's Own Stock On November 16, 2015, the Company executed a convertible promissory note with a maximum principal amount of $250,000. Amounts received under this promissory note are issued net of a 10% original issue discount. Each payment of consideration matures one year from the date of distribution. The lender can convert the outstanding principal and accrued interest of the convertible promissory note into shares of the common stock at any time at the lesser of $0.10 per share or 50% of the lowest trade share price occurring in the previous 20 trading days prior to conversion. The Company received $50,000 upon closing of the note, net of a debt discount of $5,000, and the aggregate principal balance to be repaid being $55,000. The debt discount was recorded as a reduction of the convertible debenture and is being amortized over the life of the convertible debenture. The Company valued the conversion features on this advance at origination at $68,328 using the Black Scholes valuation model with the following assumptions: dividend yield of zero, 12-month term to maturity, risk free interest rate of 0.5% and annualized volatility of 112%. $55,000 of the value assigned to the derivative liability was recognized as a debt discount on the convertible debenture. The debt discount was recorded as reduction to the convertible debenture and is being amortized over the life of the convertible debenture. The balance of $13,328 of the value assigned to the derivative liability was recognized as origination interest on the derivative liability and expensed on origination. ASC 815 requires assessment of the fair market value of derivative liability at the end of each reporting period and recognition of any change in the fair market value as other income or expense. On January 6, 2016, the Company executed a convertible promissory note in the amount of $30,000. The note does not bear interest, however, the Company would incur a re-payment penalty of $7,500 if it chose to repay the note rather than allow conversion. The lender canconvert the outstanding principal and accrued interest of the convertible promissory note into shares of the common stock at 58% of the lowest trade share price occurring in the previous 20 trading daysprior to conversion.The Company valued the conversion features on this note at origination at $26,058using the Black Scholes valuation model with the following assumptions: dividend yield of zero, 6-month term to maturity, risk free interest rate of 0.65% and annualized volatility of 111%. The Company recorded a debt discount of $30,000 as reduction to the convertible debenture and is being amortized over the life of the convertible debenture. The difference of $3,942 of the value assigned to the derivative liability was recognized as origination interest on the derivative liability and expensed on origination. ASC 815 requires assessment of the fair market value of derivative liability at the end of each reporting period and recognition of any change in the fair market value as other income or expense. On January 6, 2016, the Company executed an 8% interest convertible promissory note in the amount of $50,000, which is due and payable on January 5, 2017. The lender can convert the outstanding principal and accrued interest of the convertible promissory note into shares of the common stock at any time at 50% of the lowest trade share price occurring in the previous 20 trading days prior to conversion. The Company received $50,000 upon closing of the note and recorded a debt discount of $50,000. The debt discount was recorded as a reduction of the convertible debenture and is being amortized over the life of the convertible debenture. The Company valued the conversion features on this advances at origination at $61,876 using the Black Scholes valuation model with the following assumptions: dividend yield of zero, 12-month term to maturity, risk free interest rate of 0.65% and annualized volatility of 111%. The balance of $11,876 of the value assigned to the derivative liability was recognized as origination interest on the derivative liability and expensed on origination. ASC 815 requires assessment of the fair market value of derivative liability at the end of each reporting period and recognition of any change in the fair market value as other income or expense. On February 11, 2016, the Company executed a 10% interest convertible promissory note in the amount of $55,000, which is due and payable February 11, 2017. The lender can convert the outstanding principal and accrued interest of the convertible promissory note into shares of the common stock at 50% of the lowest trade share price occurring in the previous 20 trading days prior to conversion. The Company received $50,000 upon closing of the note, net of a debt discount of $5,000, and the aggregate principal balance to be repaid being $55,000. The debt discount was recorded as a reduction (contra-liability) of the convertible debenture and was amortized over the life of the convertible debenture. The Company valued the conversion features on this advances at origination at $70,242 using the Black Scholes valuation model with the following assumptions: dividend yield of zero, 12-month term to maturity, risk free interest rate of 0.65% and annualized volatility of 121%. $55,000 of the value assigned to the derivative liability was recognized as a debt discount on the convertible debenture. The debt discount was recorded as reduction to the convertible debenture and is being amortized over the life of the convertible debenture. The balance of $15,242 of the value assigned to the derivative liability was recognized as origination interest on the derivative liability and expensed on origination. ASC 815 requires assessment of the fair market value of derivative liability at the end of each reporting period and recognition of any change in the fair market value as other income or expense. On February 23, 2016, the Company executed an 8% interest convertible promissory note in the amount of $50,000, which is due and payable February 22, 2017. The lender can convert the outstanding principal and accrued interest of the convertible promissory note into shares of the common stock at any time at 50% of the lowest trade share price occurring in the previous 20 trading days prior to conversion. The Company valued the conversion features on this advances at origination at $63,856 using the Black Scholes valuation model with the following assumptions: dividend yield of zero, 12-month term to maturity, risk free interest rate of 0.65% and annualized volatility of 121%. $50,000 of the value assigned to the derivative liability was recognized as a debt discount on the convertible debenture. The debt discount was recorded as reduction to the convertible debenture and is being amortized over the life of the convertible debenture. The balance of $13,856 of the value assigned to the derivative liability was recognized as origination interest on the derivative liability and expensed on origination. ASC 815 requires assessment of the fair market value of derivative liability at the end of each reporting period and recognition of any change in the fair market value as other income or expense. On March 24, 2016, the Company executed a 10% interest convertible promissory note in the amount of $52,500. The lender can convert the outstanding principal and accrued interest of the convertible promissory note into shares of the common stock at any time at the lesser of $0.10 per share or 50% of the lowest trade share price occurring in the previous 20 trading days prior to conversion. The Company received $50,000 upon closing of the note, net of a debt discount of $2,500, and the aggregate principal balance to be repaid being $52,500. The debt discount was recorded as a reduction of the convertible debenture and is being amortized over the life of the convertible debenture. The Company valued the conversion features on this advances at origination at $66,633 using the Black Scholes valuation model with the following assumptions: dividend yield of zero, 12-month term to maturity, risk free interest rate of 0.65% and annualized volatility of 119%. $52,500 of the value assigned to the derivative liability was recognized as a debt discount on the convertible debenture. The debt discount was recorded as reduction to the convertible debenture and was amortized over the life of the convertible debenture. The balance of $14,133 of the value assigned to the derivative liability was recognized as origination interest on the derivative liability and expensed on origination. ASC 815 requires assessment of the fair market value of derivative liability at the end of each reporting period and recognition of any change in the fair market value as other income or expense. Changes in Derivative Liabilities June 30, 2015 $ — Value acquired during the period 356,994 Settled on issuance of common stock — Settled on payment of outstanding principal and interest — Revaluation on settlement on issuance of common stock or reporting date (9,077 ) March 31, 2016 $ 347,917

Deferred Lease Obligations

Deferred Lease Obligations	9 Months Ended
	Mar. 31, 2016
Deferred Lease Obligations
Deferred Lease Obligations	NOTE 8 – DEFERRED LEASE OBLIGATIONS Plandaí’s subsidiaries have two long-term, material leases which either have escalating terms or included several months of “free” rent, including the 49-year notarial lease for the Senteeko Tea Estate. In accordance with US Generally Accepted Accounting Principles, the Company has calculated a straight-line monthly cost on the leases and recorded the corresponding difference between the amount actually paid and the amount calculated as a Deferred Lease Obligation. As of March 31, 2016 and June 30, 2015 the amount of this deferred liability was $1,501,182 and $1,513,976, respectively. Plandaí’s subsidiary, Dunn Roman Holdings – Africa (Pty) Ltd., executed a sublease on the Bonokado Farm in South Africa to a third party. Bonokado currently farms avocado and macadamia nuts, neither of which factor into the Company’s future business model. The lease is for 20 years and includes 24 months of deferred rent while the farm is rehabilitated by the sub-lessor. In accordance with US Generally Accepted Accounting Principles, the Company has calculated a straight-line monthly value attributable to the lease and recorded the corresponding difference between the amount actually paid and the amount calculated as a Lease Receivable in Other Assets. As of March 31, 2016 and June, 2015, the amount of this receivable was $108,468 and $91,470, respectively.

Foreign Currency Translation Ad

Foreign Currency Translation Adjustment	9 Months Ended
	Mar. 31, 2016
Foreign Currency [Abstract]
Foreign Currency Translation Adjustment	NOTE 9 – FOREIGN CURRENCY TRANSLATION ADJUSTMENT The Company’s principle operations are located in South Africa and the primary currency used is the South African Rand. Accordingly, the financial statements are first prepared in using Rand and then converted to US Dollars for reporting purposes, with the average conversion rate between July and September being used for income statement purposes and the closing exchange rate as of September 30 applied to the balance sheet. Differences resulting from the fluctuation in the exchange rate are recorded as an offset to equity in the balance sheet. In the three months ended March 31, 2016 and 2015, the Company recorded a foreign currency translation adjustment gain (loss) of $(74,097) and $145,449, respectively. In the nine months ended March 31, 2016 and 2015, the Company recorded a foreign currency translation adjustment gain (loss) of $575,160 and ($432,361), respectively.

Other Income And Expense

Other Income And Expense	9 Months Ended
	Mar. 31, 2016
Other Income and Expenses [Abstract]
Other Income and Expense	NOTE 10 – OTHER INCOME AND EXPENSE For the nine months ended March 31, 2016,Other Income consisted principally of $273,922 received as a one-time grant from the South African government. For the nine months ended March 31, 2015, Other Income consisted principally of $777,724 received as part of a settlement agreement resulting from delays in completing the Senteeko factory in South Africa. For the three months ended March 31, 2015, Other Income was $12,765, which consisted of the proceeds from an insurance claim.

Common Stock

Common Stock	9 Months Ended
	Mar. 31, 2016
Common Stock
Common Stock	NOTE 11 – COMMON STOCK During the ninemonths ended March 31, 2016, the Company issued a total of 15,986,300 shares of restricted common stock as follows: 1. The Company issued 10,681,300 restricted common shares for $293,660 cash. 2. The Company issued 5,305,000 restricted common shares for services valued at $273,350. Common Stock Issuable Pursuant to two agreements executed on March 1, 2013 by the Company with two of its officers, the Company is obligated to issue 3,000,000 common shares at the end of each completed year for services rendered to the Company. The Company records the value of these shares on quarterly basis based on the value of the stock on the date of the agreements (March 1, 2013). As of March 31, 2016 and June 30, 2015, the common shares issuable pursuant to the employment agreements were $0 and $45,000, respectively. Common stock issuable at March 31, 2016 consisted of $50,000, which represented the proceeds received from two individuals who purchased shares of restricted common stock which had not been issued as of March 31, 2016.

Warrants

Warrants	9 Months Ended
	Mar. 31, 2016
Warrants
Warrants	NOTE 12 – WARRANTS On January 28, 2014, the Company signed an agreement with Diego Pellicer, Inc. under which the Company received a license to use the Diego Pellicer name and likeness on a future cannabis-based extract which is under development. As consideration for the license, the Company issued warrants to purchase 5,000,000 shares of the Company’s common stock at a purchase price of $0.01 per share. The Company originally recorded a value of $5,749,985 as an asset. However, as the cannabis extract was still in development, the intangible licenses asset balance was deemed fully impaired as of June 30, 2014, leaving a zero asset balance. Accordingly, the Company recorded an impairment expense of $5,749,985. Should the cannabis extract come to market, the value of the license will be re-evaluated. On November 10, 2015, the Company issued warrants to purchase 2,500,000 shares of the Company’s common stock at an exercise price of $0.10 per share, such warrants expiring three years after issuance. The warrants were issued as part of a stock purchase agreement with a third party. The following table summarizes share warrants activity for the periods presented: Number of Share Warrants Weighted Average Exercise Price ($) per Share Weighted Average Remaining Contractual Life Warrants outstanding, June 30, 2015 3,333,334 $ 0.01 8.5 years Issued 2,500,000 0.10 2.7 years Exercised — — — Cancelled — — — Expired — — — Warrants outstanding, March 31, 2016 5,833,334 $ 0.05 5.6 years Warrants exercisable, March 31, 2016 5,833,334 $ 0.05 5.6 years The following table summarizes information about warrants outstanding as of March 31, 2016: Exercise Price Number of Warrants Outstanding Weighted Average Life of Warrants Outstanding In Years $ 0.01 3,333,334 7.8 years $ 0.10 2,500,000 2.7 years 5,833,334

Non-Controlling Interest

Non-Controlling Interest	9 Months Ended
	Mar. 31, 2016
DisclosureMinorityInterestAbstract
Non-Controlling Interest	NOTE 13 – NON-CONTROLLING INTEREST Plandaí owns 100% of Dunn Roman Holdings—Africa, which in turn owns 74% of Breakwood Trading 22 (Pty), Ltd. and 84% of Green Gold Biotechnologies (Pty), Ltd., in order to be compliant with the Black Economic Empowerment rules imposed by the South African Land Bank. While the Company, under the Equity Method of Accounting, is required to consolidate 100% of the operations of its majority-owned subsidiaries, that portion of subsidiary net equity attributable to the minority ownership, together with an allocated portion of net income or net loss incurred by the subsidiaries, must be reflected on the consolidated financial statements. On the balance sheet, minority interest has been shown in the Equity Section, separated from the equity of Plandaí, while on the income statement, the minority shareholder allocation of net loss has been shown in the Consolidated Statement of Operations.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2016
Related Party Transactions
Related Party Transactions	NOTE 14 – RELATED PARTY TRANSACTIONS The Company had the following related party transactions during the nine months ended March 31, 2016. Related Party Payables As of March 31, 2016 and June 30, 2015, the Company owed a total of $14,890 and $16,177, respectively,to Roger Duffield, our Chief Executive Officer, for advances made to one of the Company’s South African subsidiaries in the ordinary course of business. The advances are non-interest bearing and payable on demand. Compensation to Officers and Management Pursuant to employment agreements executed on March 2, 2013 with two of the Company’s officers, the Company is also obligated to issue 3,000,000 common shares at the end of each completed year for services rendered to the Company. At March 31, 2016 and June 30, 2015, with regards to the future issuance of 3,000,000 shares, the Company accrued compensation expense for services completed in the amount of $0 and $45,000, respectively, as common stock issuable.

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2016
Subsequent Events
Subsequent Events	NOTE 15 – SUBSEQUENT EVENTS Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855 and has determined that no material subsequent events exist through the date of this filing apart from the following: • Between April 2016 and August 1, 2016, the Company sold 6,125,000 shares of restricted common stock to unaffiliated third parties for cash of $75,000. The issuance of these shares was exempt from registration under the Securities Act in reliance on an exemption provided by Section 4(2) of that Act. • Between April 2016 and August 1, 2016, the Company issued a total of $242,500 in convertible promissory notes to various third parties, receiving net proceeds of $225,000. The difference between the face value of the note and net proceeds includes loan origination fees, legal fees, and prepaid interest. The notes are due between February and June, 2017. The notes convert at a discount to market of 50% off the lowest intra-day trading price over the 15-20 day period prior to conversion. The notes bear interest between 8-10%.

Summary Of Accounting Policies

Summary Of Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2016
Summary Of Accounting Policies Policies
Basis of Presentation	Basis of Presentation The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The accompanying financial statements represent the results of operations for the three and nine months ended March 31, 2016 and March 31, 2015. The Company has adopted the US dollar as the reporting currency for accounting and reporting purposes. This summary of accounting policies for Plandaí Biotechnology, Inc. and its wholly-owned subsidiaries, is presented to assist in understanding the Company's financial statements. The accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the financial statements.
Interim Financial Statements	Interim Financial Statements The accompanying financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to form 10Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion the financial statements include all adjustments (consisting of normal recurring accruals) necessary in order to make the financial statements not misleading. Operating results for the three and nine months ended March 31, 2016 are not necessarily indicative of the final results that may be expected for the year ended June 30, 2016. For more complete financial information, these unaudited financial statements should be read in conjunction with the audited financial statements for the year ended June 30, 2015 filed with the SEC.
Use of Estimates	Use of Estimates The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America. In preparing the financial statements, management is required to make estimates and assumptions that effect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the balance sheet and statement of operations for the year then ended. Actual results may differ from these estimates. Estimates are used when accounting for allowance for bad debts, collect ability of accounts receivable, amounts due to service providers, depreciation and litigation contingencies, among others.
Business Combinations and Acquisitions	Business Combinations and Acquisitions The disclosure requirements for business combination and acquisitions are intended to enable users of financial statements to evaluate the nature and financial effects of: • A business combination that occurs either during the current reporting period or after the reporting period, but before the financial statements are issued • Adjustments recognized in the current reporting period that relate to business combinations that occurred in current and previous reporting periods • The nature of the relationship between the parent and a subsidiary or investee when the parent does not have 100 percent ownership or control The Company discloses each material business combination in the period in which the business combination occurs. The Company also discloses information about acquisitions made after the balance sheet date, but before the financial statements are issued. Gains or losses arising from the deconsolidation of a business when the company loses control of that business are also disclosed. Acquisition costs incurred such as legal, advisory and consulting fees are expensed as incurred. In accordance with ASC 805-10-25-1, ASC 805-10-05-4 and IFRS 3.4, 5, the Company employs the Acquisition Method of accounting for routine acquisitions and combinations.
Net Loss Per Common Share	Net Loss Per Common Share The Company adopted FASB ASC Topic 260, Earnings Per Share In January 2014, the Company issued warrants to purchase 5,000,000 shares of the Company’s common stock which have a strike price of $0.01/share; however, since the Company incurred a loss for all periods presented, the warrants are considered anti-dilutive. During the year ended June 30, 2015, a total of 1,666,666 warrants were exercised utilizing a “cashless” option resulting in the issuance of 1,629,212 shares of restricted common stock, leaving 3,333,334 outstanding exercisable warrants as of March 31, 2016.
Reclassifications	Reclassifications Prior year amounts have been reclassified to conform to the current year presentation. There was no net impact on total assets, net (loss), comprehensive (loss) or the statement of cash flows.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Mar. 31, 2016
Fixed Assets Tables
Schedule of Fixed Assets	Fixed assets, stated at cost, less accumulated depreciation at March 31, 2016 and June 30, 2015 consisted of the following: March 31, June 30, Plant and Equipment $ 6,188,185 $ 7,487,506 Machinery and Equipment 172,172 211,283 Leasehold Improvements 666,320 752,530 Furniture and Fixtures 67,756 81,626 Automobiles 75,275 90,684 Computers and Equipment 19,263 23,206 Total Fixed Assets 7,188,971 8,646,835 Less: Accumulated Depreciation (912,679 ) (636,879 ) Fixed Assets, net $ 6,276,292 $ 8,009,956

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Mar. 31, 2016
Segment Information Tables
Schedule of Segment Information	The following information summarizes the financial information regarding Plandaí Biotechnology Inc. and its operational South African subsidiaries for the periods presented: As of June 30, 2015: South Africa United States Total Assets $ 8,406,177 $ 98,404 $ 8,504,581 Liabilities $ 10,402,092 $ 6,419,225 $ 16,821,317 As of March 31, 2016 South Africa United States Total Assets $ 6,578,361 $ 47,427 $ 6,625,788 Liabilities $ 9,245,853 $ 7,826,858 $ 17,072,711 For the three-months ended March 31, 2016 South Africa United States Total Revenues from external customer $ 100,295 $ — $ 100,295 Expenses $ 468,508 $ 356,686 $ 825,194 Interest expense $ 179,031 $ 196,211 $ 375,242 Segment loss $ 547,244 $ 547,567 $ 1,094,811 For the nine-months ended March 31, 2016 South Africa United States Total Revenues from external customer $ 197,798 $ — $ 197,798 Expenses $ 1,545,972 $ 942,945 $ 2,488,917 Interest expense $ 556,070 $ 450,926 $ 1,006,996 Segment loss $ 1,630,322 $ 1,384,794 $ 3,015,116

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Mar. 31, 2016
Notes Payable Tables
Schedule of Long Term Loan Balance	As of the dates presented, the long-term loan balances were as follows: Interest Rate Due Date March 31, 2016 June 30, 2015 Loan Principle and Interest - Land Bank See below See below $ 7,369,404 $ 8,401,900 Notes Payable – other third party 6% July 1, 2016 6,900,000 6,500,000 Less: Discount (327,384 ) (375,687 ) 13,942,020 14,526,213 Less: Current Portion (13,942,020 ) (14,526,213 ) Long Term Debt, Net of Discount $ — $ —
Schedule of Future Maturity of Long Term Debt	Future maturities of long-term debt are as follows: 2016 $ 8,640,000 2017 1,740,000 2018 1,740,000 2019 1,740,000 2020 82,020 $ 13,942,020

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Principal Balance Loan Discount Accrued interest Total June 30,2015 $ — $ — $ — $ — Issued in the period 292,500 (288,558 ) — 3,942 Converted into shares of common stock — — — — Payments of principal and interest — — — — Amortization of debt discount — 4,389 — 4,389 Interest accrued — — — — March 31, 2016 $ 292,500 $ (284,169 ) $ — $ 8,331
Schedule of Changes in Derivative Liabilities	Changes in Derivative Liabilities June 30, 2015 $ — Value acquired during the period 356,994 Settled on issuance of common stock — Settled on payment of outstanding principal and interest — Revaluation on settlement on issuance of common stock or reporting date (9,077 ) March 31, 2016 $ 347,917

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Mar. 31, 2016
Warrants Tables
Schedule of Warrants Activity	The following table summarizes share warrants activity for the periods presented: Number of Share Warrants Weighted Average Exercise Price ($) per Share Weighted Average Remaining Contractual Life Warrants outstanding, June 30, 2015 3,333,334 $ 0.01 8.5 years Issued 2,500,000 0.10 2.7 years Exercised — — — Cancelled — — — Expired — — — Warrants outstanding, March 31, 2016 5,833,334 $ 0.05 5.6 years Warrants exercisable, March 31, 2016 5,833,334 $ 0.05 5.6 years
Schedule of Warrants Outstanding	The following table summarizes information about warrants outstanding as of March 31, 2016: Exercise Price Number of Warrants Outstanding Weighted Average Life of Warrants Outstanding In Years $ 0.01 3,333,334 7.8 years $ 0.10 2,500,000 2.7 years 5,833,334

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Total Fixed Assets	$ 7,188,971	$ 8,646,835
Less: Accumulated Depreciation	912,679	636,879
Fixed Assets, net	6,276,292	8,009,956
Plant And Equipment [Member]
Property, Plant and Equipment [Line Items]
Total Fixed Assets	6,188,185	7,487,506
Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Total Fixed Assets	172,172	211,283
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total Fixed Assets	666,320	752,530
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total Fixed Assets	67,756	81,626
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Total Fixed Assets	75,275	90,684
Computers And Equipment [Member]
Property, Plant and Equipment [Line Items]
Total Fixed Assets	$ 19,263	$ 23,206

Segment Information (Details)

Segment Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015
Assets	$ 6,625,788		$ 6,625,788		$ 8,504,581
Liabilities	17,072,711		17,072,711		16,821,317
Revenues from external customer	100,295	$ 21,744	197,798	$ 64,024
Expenses	825,194	6,011,002	2,488,917	8,434,432
Interest expense	375,242	296,292	1,006,996	552,344
Segment loss	(1,094,811)	$ (6,272,785)	(3,015,116)	$ (8,145,028)
South Africa [Member]
Assets	6,578,361		6,578,361		8,406,177
Liabilities	9,245,853		9,245,853		10,402,092
Revenues from external customer	100,295		197,798
Expenses	468,508		1,545,972
Interest expense	179,031		556,070
Segment loss	(547,244)		(1,630,322)
United States [Member]
Assets	47,427		47,427		98,404
Liabilities	7,826,858		7,826,858		$ 6,419,225
Revenues from external customer
Expenses	356,686		942,945
Interest expense	196,211		450,926
Segment loss	$ (547,567)		$ (1,384,794)

Notes Payable (Schedule Of Long

Notes Payable (Schedule Of Long Term Loan Balance) (Details) - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2016	Jun. 30, 2015
Debt Instrument [Line Items]
Loan Principle and Interest - Land Bank	$ 7,369,404	$ 8,401,900
Notes Payable - other third party	6,900,000	6,500,000
Less: Discount	327,384	375,687
Long Term Debt, Net of Unamortized Discount	13,942,020	14,526,213
Less: Current Portion	13,942,020	14,526,213
Long Term Debt, Net of Discount
Notes Payable - Third Party [Member]
Debt Instrument [Line Items]
Interest Rate	6.00%	6.00%
Due Date	Jul. 1, 2016	Jul. 1, 2016

Notes Payable (Schedule Of Futu

Notes Payable (Schedule Of Future Maturity Of Long Term Debt) (Details)	Mar. 31, 2016USD ($)
Future maturities of long-term debt:
2,016	$ 8,640,000
2,017	1,740,000
2,018	1,740,000
2,019	1,740,000
2,020	82,020
Total	$ 13,942,020

Convertible Notes Payable (Sche

Convertible Notes Payable (Schedule Of Convertible Notes Payable) (Details)	9 Months Ended
	Mar. 31, 2016USD ($)
Short-term Debt [Line Items]
Beginning of the period
Issued in the period	3,942
Converted into shares of common stock
Payments of principal and interest
Amortization of debt discount	4,389
Interest accrued
End of the period	8,331
Principal Balance [Member]
Short-term Debt [Line Items]
Beginning of the period
Issued in the period	292,500
Converted into shares of common stock
Payments of principal and interest
Amortization of debt discount
Interest accrued
End of the period	292,500
Loan Discount [Member]
Short-term Debt [Line Items]
Beginning of the period
Issued in the period	(288,558)
Converted into shares of common stock
Payments of principal and interest
Amortization of debt discount	4,389
Interest accrued
End of the period	(284,169)
Accrued Interest [Member]
Short-term Debt [Line Items]
Beginning of the period
Issued in the period
Converted into shares of common stock
Payments of principal and interest
Amortization of debt discount
Interest accrued
End of the period

Convertible Notes Payable (Sc32

Convertible Notes Payable (Schedule Of Changes In Derivative Liabilities) (Details) - Derivative Liabilites [Member]	9 Months Ended
	Mar. 31, 2016USD ($)
Changes in Derivative Liabilities
Beginning of the period
Value acquired during the period	356,994
Settled on issuance of common stock
Settled on payment of outstanding principal and interest
Revaluation on settlement on issuance of common stock or reporting date	(9,077)
End of the period	$ 347,917

Warrants (Schedule Of Warrants

Warrants (Schedule Of Warrants Activity) (Details) - Warrants [Member]	9 Months Ended
	Mar. 31, 2016$ / sharesshares
Number of Share Warrants
Warrants outstanding at the beginning | shares	3,333,334
Issued | shares	2,500,000
Exercised | shares
Cancelled | shares
Expired | shares
Warrants outstanding at the end | shares	5,833,334
Warrants exercisable at the end | shares	5,833,334
Weighted Average Exercise Price ($) per Share
Warrants outstanding at the beginning | $ / shares	$ 0.01
Issued | $ / shares	0.10
Exercised | $ / shares
Cancelled | $ / shares
Expired | $ / shares
Warrants outstanding at the end | $ / shares	0.05
Warrants exercisable at the end | $ / shares	$ 0.05
Weighted Average Remaining Contractual Life
Warrants outstanding at the beginning	8 years 5 months
Issued	2 years 8 months 12 days
Warrants outstanding at the end	5 years 7 months 6 days
Warrants exercisable at the end	5 years 7 months 6 days

Warrants (Schedule Of Warrant34

Warrants (Schedule Of Warrants Outstanding) (Details) - Warrants [Member] - $ / shares	9 Months Ended
	Mar. 31, 2016	Jun. 30, 2015
Number of Warrants Outstanding	5,833,334	3,333,334
Weighted Average Life of Warrants Outstanding In Years	5 years 7 months 6 days
Exercise Price 0.01 [Member]
Exercise Price	$ 0.01
Number of Warrants Outstanding	3,333,334
Weighted Average Life of Warrants Outstanding In Years	7 years 9 months 18 days
Exercise Price 0.10 [Member]
Exercise Price	$ 0.10
Number of Warrants Outstanding	2,500,000
Weighted Average Life of Warrants Outstanding In Years	2 years 8 months 12 days

Summary Of Accounting Policie35

Summary Of Accounting Policies (Narrative) (Details)	12 Months Ended
	Jun. 30, 2015shares
Warrants [Member]
No of warrants exercised	1,666,666
Restricted Common Stock [Member]
Stock issued in exercise of warrants	1,629,212

Notes Payable (Narrative) (Deta

Notes Payable (Narrative) (Details)	1 Months Ended		3 Months Ended	9 Months Ended			12 Months Ended
	Jul. 31, 2015USD ($)	Jun. 30, 2012USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2016ZAR	Mar. 31, 2015USD ($)	Jun. 30, 2015USD ($)shares	Jun. 30, 2012USD ($)shares	Jun. 04, 2015USD ($)	Jun. 30, 2012ZAR
Debt Instrument [Line Items]
Accrued interest			$ 598,410	$ 598,410			$ 288,612
Amortization of debt discount				52,691
Unamortized debt discount			327,384	327,384			375,687
Notes payable includes capitalized accrued interest			$ 7,369,404	7,369,404			$ 8,401,900
Repayment of long term debt				$ 154,009
Restricted Common Stock [Member]
Debt Instrument [Line Items]
Shares issued for settlement, shares | shares							1,629,212
Notes Payable - Third Party [Member]
Debt Instrument [Line Items]
Debt instrument face amount									$ 6,500,000
Debt instrument interest rate			6.00%	6.00%			6.00%
Debt instrument maturity date				Jul. 1, 2016	Jul. 1, 2016		Jul. 1, 2016
Notes payable to third party			$ 6,900,000	$ 6,900,000			$ 6,500,000
Debt description				These notes were due and payable twelve months after issuance. The Company subsequently renegotiated the due date on each of these notes to July 1, 2016. The Company is not required to make monthly payments on any of these notes.	These notes were due and payable twelve months after issuance. The Company subsequently renegotiated the due date on each of these notes to July 1, 2016. The Company is not required to make monthly payments on any of these notes.		These notes were due and payable twelve months after issuance. The Company subsequently renegotiated the due date on each of these notes to July 1, 2016. The Company is not required to make monthly payments on any of these notes.
Accrued interest			594,332	$ 594,332			$ 288,612
Notes Payable Issued On July 2015 - Third Party [Member]
Debt Instrument [Line Items]
Debt instrument face amount	$ 400,000
Debt instrument interest rate	6.00%
Proceeds from notes payable	$ 384,170
Debt issuance cost	$ 15,830
Debt instrument maturity date	Feb. 1, 2016
Loan - Land And Agriculture Bank Of South Africa [Member]
Debt Instrument [Line Items]
Amortization of debt discount			16,101	48,303
Unamortized debt discount			327,384	327,384
Notes payable includes capitalized accrued interest			7,369,404	$ 7,369,404
Debt repayment terms				As the 25-month holiday in which no payments or interest are due expired in July of 2014.	As the 25-month holiday in which no payments or interest are due expired in July of 2014.
Monthly payments towards long term debt				$ 145,000
Repayment of long term debt				162,329
Capitalized accrued interest			$ 559,088	$ 559,088
Loan - Land And Agriculture Bank Of South Africa [Member] | Restricted Common Stock [Member]
Debt Instrument [Line Items]
Debt description								The acquired Dunn Roman shares were then provided to third parties in order to comply with the BEE provisions associated with the loan from the Land Bank of South Africa, which required that 15% of Dunn Roman be owned by non-white South Africans. The Company has therefore determined to treat the value of the shares issued to acquire the Dunn Roman stock ($585,000, based on the value of shares on the date of issuance) as a cost of securing the financing and recorded as a loan discount which is amortized over the life of the loan (7 years).
Shares issued for settlement, shares | shares								1,500,000
Shares issued as loan origination fee, value								$ 585,000
Loan - Land And Agriculture Bank Of South Africa [Member] | South Africa, Rand [Member]
Debt Instrument [Line Items]
Monthly payments towards long term debt | ZAR					ZAR 2,250,000
Loan - Land And Agriculture Bank Of South Africa [Member] | Dunn Roman Holdings-Africa, Ltd [Member]
Debt Instrument [Line Items]
Debt instrument face amount		$ 6,500,000						$ 6,500,000
Debt description		In addition, the loans have a 25-month “holiday” in which no payments or interest are due until 25 months after the first draw down of funds. The loans are collateralized by the assets and operations, including the Senteeko lease, agriculture production and receivables of Dunn Roman Holdings, which is the African operating arm of Plandaí. In addition, Dunn Roman Holdings was required to grant a 15% profit share agreement to the Land Bank which extends through the duration of the loan agreements (7 years unless pre-paid). The profit share agreement extends only to profits generated by Dunn Roman Holdings exclusive of operations of Plandaí and outside of South Africa.
Interest rate on loan		Prime plus 0.50 % per annum
Debt duration		7 years
Debt executed through		Green Gold Biotechnologies (Pty) Ltd and Breakwood Trading 22(Pty) Ltd
Debt covenants description		By way of loan covenants, the borrowing entities are required to maintain a debt to equity ratio of 1.5:1, interest coverage ratio of 1.5:1, and security coverage ratio of 1:1, none of which are currently in compliance.
Loan - Land And Agriculture Bank Of South Africa [Member] | Dunn Roman Holdings-Africa, Ltd [Member] | South Africa, Rand [Member]
Debt Instrument [Line Items]
Debt instrument face amount | ZAR										ZAR 100,000,000

Notes Payable To Related Part37

Notes Payable To Related Parties (Narrative) (Details)	Jan. 02, 2016GBP (£)	Mar. 31, 2016USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)
Short-term Debt [Line Items]
Proceeds from notes payable to related party			$ 50,526
Promissory Notes Dated January 01, 2016 [Member] | Son Of Roger Duffield - (CEO) [Member]
Short-term Debt [Line Items]
Proceeds from notes payable to related party		$ 52,526
Debt instrument interest rate	15.00%
Debt instrument description	The note bears interest at the rate of 15% per annum, with interest due semi-annually, and the balance plus any accrued interest due.
Debt instrument maturity date	Dec. 31, 2016
Promissory Notes Dated January 01, 2016 [Member] | Son Of Roger Duffield - (CEO) [Member] | Pounds [Member]
Short-term Debt [Line Items]
Debt instrument face amount | £	£ 35,000

Convertible Notes Payable (Narr

Convertible Notes Payable (Narrative) (Details) - USD ($)	Mar. 24, 2016	Feb. 23, 2016	Feb. 11, 2016	Jan. 06, 2016	Nov. 16, 2015	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015
Short-term Debt [Line Items]
Proceeds from convertible notes						$ 275,000
Valuation techniques used in determining the fair value of derivative liability:
Derivative liability, debt discount unamortized						$ 327,384		$ 375,687
Convertible Promissory Note Issued On November 16, 2015 [Member]
Short-term Debt [Line Items]
Debt instrument face amount					$ 250,000
Debt instrument rate of original issue discount					10.00%
Debt instrument maturity description					Each payment of consideration matures one year from the date of distribution.
Debt conversion terms					The lender can convert the outstanding principal and accrued interest of the convertible promissory note into shares of the common stock at any time at the lesser of $0.10 per share or 50% of the lowest trade share price occurring in the previous 20 trading days prior to conversion.
Proceeds from convertible notes					$ 50,000
Unamortized debt discount					5,000
Debt instrument carrying amount					55,000
Valuation of debt at origination					$ 68,328
Valuation techniques used in determining the fair value of derivative liability:
Derviative liability valuation model used					Black Scholes valuation model
Derviative liability, dividend yield					0.00%
Derviative liability, maturity term					12 months
Derviative liability, risk-free interest rate					0.50%
Derviative liability, expected volatility					112.00%
Derivative liability, debt discount unamortized					$ 55,000
Loss of derivative liability was recognized as origination interest					$ 13,328
Convertible Promissory Note Issued On January 6, 2016 [Member]
Short-term Debt [Line Items]
Debt instrument face amount				$ 30,000
Debt conversion terms				The lender can convert the outstanding principal and accrued interest of the convertible promissory note into shares of the common stock at 58% of the lowest trade share price occurring in the previous 20 trading days prior to conversion.
Valuation of debt at origination				$ 26,058
Valuation techniques used in determining the fair value of derivative liability:
Derviative liability valuation model used				Black Scholes valuation model
Derviative liability, dividend yield				0.00%
Derviative liability, maturity term				6 months
Derviative liability, risk-free interest rate				0.65%
Derviative liability, expected volatility				111.00%
Derivative liability, debt discount unamortized				$ 30,000
Loss of derivative liability was recognized as origination interest				$ 3,942
Debt instrument description				The note does not bear interest, however, the Company would incur a re-payment penalty of $7,500 if it chose to repay the note rather than allow conversion
Convertible Promissory Note Issued On January 6, 2016 [Member]
Short-term Debt [Line Items]
Debt instrument face amount				$ 50,000
Debt conversion terms				The lender can convert the outstanding principal and accrued interest of the convertible promissory note into shares of the common stock at any time at 50% of the lowest trade share price occurring in the previous 20 trading days prior to conversion.
Proceeds from convertible notes				$ 50,000
Unamortized debt discount				50,000
Valuation of debt at origination				$ 61,876
Valuation techniques used in determining the fair value of derivative liability:
Derviative liability, dividend yield				0.00%
Derviative liability, maturity term				12 months
Derviative liability, risk-free interest rate				0.65%
Derviative liability, expected volatility				111.00%
Loss of derivative liability was recognized as origination interest				$ 11,876
Debt instrument interest rate				8.00%
Debt instrument maturity date				Jan. 5, 2017
Convertible Promissory Note Issued On February 11, 2016 [Member]
Short-term Debt [Line Items]
Debt instrument face amount			$ 55,000
Debt conversion terms			The lender can convert the outstanding principal and accrued interest of the convertible promissory note into shares of the common stock at 50% of the lowest trade share price occurring in the previous 20 trading days prior to conversion.
Proceeds from convertible notes			$ 50,000
Unamortized debt discount			5,000
Debt instrument carrying amount			55,000
Valuation of debt at origination			$ 70,242
Valuation techniques used in determining the fair value of derivative liability:
Derviative liability, dividend yield			0.00%
Derviative liability, maturity term			12 months
Derviative liability, risk-free interest rate			0.65%
Derviative liability, expected volatility			121.00%
Derivative liability, debt discount unamortized			$ 55,000
Loss of derivative liability was recognized as origination interest			$ 15,242
Debt instrument interest rate			10.00%
Debt instrument maturity date			Feb. 11, 2017
Convertible Promissory Note Issued On February 23, 2016 [Member]
Short-term Debt [Line Items]
Debt instrument face amount		$ 50,000
Debt conversion terms		The lender can convert the outstanding principal and accrued interest of the convertible promissory note into shares of the common stock at any time at 50% of the lowest trade share price occurring in the previous 20 trading days prior to conversion.
Valuation of debt at origination		$ 63,856
Valuation techniques used in determining the fair value of derivative liability:
Derviative liability, dividend yield		0.00%
Derviative liability, maturity term		12 months
Derviative liability, risk-free interest rate		0.65%
Derviative liability, expected volatility		121.00%
Derivative liability, debt discount unamortized		$ 50,000
Loss of derivative liability was recognized as origination interest		$ 13,856
Debt instrument interest rate		8.00%
Debt instrument maturity date		Feb. 22, 2017
Convertible Promissory Note Issued On March 24, 2016 [Member]
Short-term Debt [Line Items]
Debt instrument face amount	$ 52,500
Debt conversion terms	The lender can convert the outstanding principal and accrued interest of the convertible promissory note into shares of the common stock at any time at the lesser of $0.10 per share or 50% of the lowest trade share price occurring in the previous 20 trading days prior to conversion.
Proceeds from convertible notes	$ 50,000
Unamortized debt discount	2,500
Debt instrument carrying amount	52,500
Valuation of debt at origination	$ 66,633
Valuation techniques used in determining the fair value of derivative liability:
Derviative liability, dividend yield	0.00%
Derviative liability, maturity term	12 months
Derviative liability, risk-free interest rate	0.65%
Derviative liability, expected volatility	119.00%
Derivative liability, debt discount unamortized	$ 52,500
Loss of derivative liability was recognized as origination interest	$ 14,133
Debt instrument interest rate	10.00%

Deferred Lease Obligations (Nar

Deferred Lease Obligations (Narrative) (Details) - USD ($)	9 Months Ended
	Mar. 31, 2016	Jun. 30, 2015
Senteeko Tea Estate [Member]
Capital lease period	49 years
SubLease On The Bonokado Farm [Member] | Other Assets [Member]
Lease receivable	$ 108,468	$ 91,470
SubLease On The Bonokado Farm [Member] | Dunn Roman Holdings-Africa, Ltd [Member]
Capital lease period	20 years
Capital lease terms	Plandaí’s subsidiary, Dunn Roman Holdings – Africa (Pty) Ltd., executed a sublease on the Bonokado Farm in South Africa to a third party. Bonokado currently farms avocado and macadamia nuts, neither of which factor into the Company’s future business model. The lease is for 20 years and includes 24 months of deferred rent while the farm is rehabilitated by the sub-lessor.

Other Income (Narrative) (Detai

Other Income (Narrative) (Details) - Other Income [Member] - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
One time grant received from the South African government		$ 273,922
Income received from settlement agreement for delays in completing the Senteeko factory			$ 777,724
Proceeds from an insurance claim	$ 12,765

Common Stock (Narrative) (Detai

Common Stock (Narrative) (Details) - USD ($)	9 Months Ended
	Mar. 31, 2016	Jun. 30, 2015
Proceeds received for common stock	$ 50,000	$ 45,000
Restricted Common Stock [Member]
Total shares issued during the period	15,986,300
Shares issued for cash, shares	10,681,300
Shares issued for cash, value	$ 293,660
Shares issued for services, shares	5,305,000
Shares issued for services, value	$ 273,350
Common Stock [Member] | Two Individuals [Member] | Common Stock Issuable [Member]
Proceeds received for common stock	$ 50,000

Warrants (Narrative) (Details)

Warrants (Narrative) (Details) - USD ($)	Nov. 10, 2015	Jan. 28, 2014	Jun. 30, 2014	Mar. 31, 2016
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued for stock purchase agreement, shares				2,500,000
Exercise price, per share				$ 0.10
License Agreement - Diego Pellicer, Inc. [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Impairment of license			$ 5,749,985
License cost			$ 0
License Agreement - Diego Pellicer, Inc. [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued for license agreement, shares		5,000,000
Purchase price, per share		$ 0.01
Stock Purchase Agreement With A Third Party [Member} | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued for stock purchase agreement, shares	2,500,000
Exercise price, per share	$ 0.10

Non-Controlling Interest (Narra

Non-Controlling Interest (Narrative) (Details)	Mar. 31, 2016
Dunn Roman Holdings-Africa, Ltd [Member]
Holding by Plandai Biotechnology Inc	100.00%
Breakwood Trading 22 (Pty) Ltd [Member]
Holding by Dunn Roman Holdings-Africa	74.00%
Green Gold Biotechnologies (Pty) Ltd [Member]
Holding by Dunn Roman Holdings-Africa	84.00%
Plandai Biotechnologies, Inc. [Member]
Equity method investment ownership percentage of its majority owned subsidiaries	100.00%

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($)	Mar. 02, 2013	Mar. 31, 2016	Jun. 30, 2015
Related Party Transaction [Line Items]
Due to related parties		$ 14,890	$ 16,177
Roger Duffield - (CEO) [Member]
Related Party Transaction [Line Items]
Due to related parties		$ 14,890	$ 16,177
Debt instrument description		The advances are non-interest bearing and payable on demand.	The advances are non-interest bearing and payable on demand.
Two Employment Agreement With Two Officers [Member]
Related Party Transaction [Line Items]
Employment agreement terms	Pursuant to employment agreements executed on March 2, 2013 with two of the Company’s officers, the Company is also obligated to issue 3,000,000 common shares at the end of each completed year for services rendered to the Company.
Two Employment Agreement With Two Officers [Member] | Common Stock Issuable [Member]
Related Party Transaction [Line Items]
Accrued compensation expenses		$ 0	$ 45,000

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) - USD ($)	4 Months Ended	9 Months Ended
	Aug. 01, 2016	Mar. 31, 2016
Restricted Common Stock [Member]
Subsequent Event [Line Items]
Shares issued for cash, shares		10,681,300
Shares issued for cash, value		$ 293,660
Subsequent Event [Member] | Convertible Promissory Notes To Various Third Parties [Member]
Subsequent Event [Line Items]
Debt instrument face amount	$ 242,500
Proceeds from notes payable	$ 225,000
Debt instrument maturity description	The notes are due between February and July, 2017.
Debt instrument conversion terms	The notes convert at a discount to market of 50% off the lowest intra-day trading price over the 15-20 day period prior to conversion.
Subsequent Event [Member] | Convertible Promissory Notes To Various Third Parties [Member] | Minimum [Member]
Subsequent Event [Line Items]
Debt instrument interest rate	8.00%
Subsequent Event [Member] | Convertible Promissory Notes To Various Third Parties [Member] | Maximum [Member]
Subsequent Event [Line Items]
Debt instrument interest rate	10.00%
Subsequent Event [Member] | Restricted Common Stock [Member] | Unaffiliated Third Parties [Member]
Subsequent Event [Line Items]
Shares issued for cash, shares	6,125,000
Shares issued for cash, value	$ 75,000